A better Ozempic? Eli Lilly’s new obesity drug cut weight by 23%, study finds

In an added benefit, more than one in eight people taking the highest dose of Retratrutide were completely free of arthritic ...
NBC 6 South Florida

Eli Lilly's Zepbound causes greater weight loss than Novo Nordisk's Wegovy in head-to-head trial

The findings suggest Zepbound may be a superior treatment for weight loss, helping obese or overweight patients lose 20.2% of their body weight, or roughly 50 pounds, on average after 72 weeks in ...
Everyday Health on MSN

New Obesity Drug Helped People Lose Nearly One-Third Their Body Weight

The clinical trial showed this experimental medication to be much more effective than any existing GLP-1 drug. But that much ...
KTVZ

Zepbound vs. Wegovy: Comparing weight loss drugs

Zepbound (tirzepatide) and Wegovy (semaglutide) are FDA-approved injectable medications revolutionizing weight management. Both belong to the incretin mimetic drug class but differ in their ...
BioPharma Dive

Lilly’s three-pronged drug puts obesity field ‘on notice’

Lilly’s closely watched retatrutide spurred as much as 29% weight loss in a Phase 3 study, a finding that is “raising the bar ...
Everyday Health

Zepbound vs. Wegovy: Which Obesity Treatment Might Be Right for You?

There’s no question that medications like semaglutide (Wegovy) and tirzepatide (Zepbound) have been making headlines lately. They’re two of the few injectable medications approved specifically for ...